Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc.
Your view on CRBP
Overview
What the company does, where it operates, and who runs it.
About Corbus Pharmaceuticals Holdings, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Yuval Cohen
- Headquarters
- 500 River Ridge Drive, Norwood, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Yuval Cohen
- Headquarters
- 500 River Ridge Drive, Norwood, MA, US
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases.
It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases.
The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation.
It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Corbus Pharmaceuticals Holdings, Inc., and the rating behind it. CRBP last traded at $8.12; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Corbus Pharmaceuticals Holdings, Inc.. Starting points for Corbus Pharmaceuticals Holdings, Inc.: EPS -$5.25, beta 2.64 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Corbus Pharmaceuticals Holdings, Inc.. Corbus Pharmaceuticals Holdings, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Corbus Pharmaceuticals Holdings, Inc.. Trailing twelve-month EPS for Corbus Pharmaceuticals Holdings, Inc. stands at -$5.25. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Corbus Pharmaceuticals Holdings, Inc.. Corbus Pharmaceuticals Holdings, Inc. has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Corbus Pharmaceuticals Holdings, Inc. valued side by side against its closest peers. Corbus Pharmaceuticals Holdings, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Corbus Pharmaceuticals Holdings, Inc., and how their positions are changing. At a $150.4M market value, institutional positions materially move Corbus Pharmaceuticals Holdings, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Corbus Pharmaceuticals Holdings, Inc. executives and directors. Shares of Corbus Pharmaceuticals Holdings, Inc. have traded between $4.64 and $20.56 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Corbus Pharmaceuticals Holdings, Inc.. Corbus Pharmaceuticals Holdings, Inc. is a $150.4M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Corbus Pharmaceuticals Holdings, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Corbus Pharmaceuticals Holdings, Inc.. Coverage tracks Corbus Pharmaceuticals Holdings, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.